002675 东诚药业
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,741,074-4.46%3,275,6483,582,9553,912,0503,418,978
减:营业总成本2,521,698-4.81%2,826,4773,034,6453,349,5202,836,583
    其中:营业成本1,344,049-11.37%1,805,9582,044,3752,309,8761,752,036
               财务费用146,99490.32%31,2936,15157,99051,628
               资产减值损失----(111,886)(80,290)(217,321)--
公允价值变动收益905-15.31%(19,474)4011,1711,047
投资收益(16,781)19.99%(8,654)(39,614)(13,325)8,722
    其中:对联营企业和合营企业的投资收益(24,039)-4.94%(37,751)(41,716)(19,962)1,326
营业利润212,639-3.70%341,662448,252356,932609,145
利润总额211,443-3.50%337,282445,576356,099611,375
减:所得税费用57,001-26.62%83,06592,74995,24993,902
净利润154,4419.20%254,216352,828260,850517,473
减:非控股权益(41,188)-2.86%44,48145,536109,28899,707
股东净利润195,6296.42%209,736307,291151,561417,766

市场价值指针
每股收益 (元) *0.2376.42%0.2540.3800.1890.521
每股派息 (元) *0.0800.00%0.1250.1500.1500.250
每股净资产 (元) *5.275-2.91%5.7915.759--5.570
审计意见 #标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容